Wyeth acquires an additional stake in Wyeth K.K. Japan.
"The partnership between Wyeth and Takeda to co-promote Enbrel should help make Japan one of the strongest markets for this important biotech product," says Bernard Poussot, President, Wyeth Pharmaceuticals.
The history of WKK begins in 1953 with Lederle (Japan), Ltd., a 50-50 joint venture between the American Cyanamid Company and the then Takeda Chemical Industries, Ltd. In 1994, American Home Products Corporation, now Wyeth, acquired American Cyanamid making it a joint venture between Wyeth and Takeda.
Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
|Printer friendly Cite/link Email Feedback|
|Publication:||BIOTECH Patent News|
|Date:||Mar 1, 2006|
|Previous Article:||Mannatech enforces its ambrotose patent against nutritional supplements firm.|
|Next Article:||Chromos signs agreement with AppTec to manufacture multiple sclerosis drug.|